Medical Condition News

RSS

New blood spot analysis method can diagnose range of clinical conditions

Scientists have developed a rapid method that can be used to simultaneously screen patients for a range of genetic and acquired clinical conditions from a single dried blood spot.

17 Nov 2011

NYU Langone recognized as leading cardiovascular hospital in the U.S.

NYU Langone Medical Center has been recognized as a leading cardiovascular hospital in the United States. The medical center received the Thomson Reuters Top 50 Cardiovascular Hospitals 2012 Award for its high-quality cardiovascular care and excellent performance in key clinical measures. The medical center is the only hospital in New York State to be honored with this year's award.

17 Nov 2011

Probiotic before radiation therapy can protect intestine from damage

Scientists at Washington University School of Medicine in St. Louis have shown that taking a probiotic before radiation therapy can protect the intestine from damage — at least in mice.

17 Nov 2011

TNF inhibitors may minimally increase risk of serious infections

Biologic drugs have revolutionized treatment of autoimmune diseases during the past decade despite belief there is an increased risk for serious infections from using them. But new research from the University of Alabama at Birmingham Center for Education and Research on Therapeutics reveals that a class of biologics called tumor necrosis factor antagonists, or TNF inhibitors, may only minimally increase risk compared to more traditional therapies.

17 Nov 2011

Teens more likely to die from heart disease at younger age than adults

A new study that takes a complete snapshot of adolescent cardiovascular health in the United States reveals a dismal picture of teens who are likely to die of heart disease at a younger age than adults do today, reports Northwestern Medicine research.

17 Nov 2011

Researchers identify hepcidin hormone as potential target for atherosclerosis

Researchers at Emory University School of Medicine have identified hepcidin, a hormone that regulates iron levels in the body, as a potential target for treating atherosclerosis.

17 Nov 2011

Study uses MRI to evaluate cardiovascular risk in WTC first responders

In the first study using magnetic resonance imaging (MRI) to evaluate cardiovascular risk in World Trade Center (WTC) first responders, researchers from Mount Sinai School of Medicine have found that the responders who experienced high levels of exposure to the initial dust cloud on September 11, 2001, demonstrate high-risk features of atherosclerosis.

17 Nov 2011

Severity of smoke-inhalation injury may play a role in overall pulmonary inflammatory response

A study of burn patients has found that those who suffered the most severe smoke inhalation also had more inflammation and spent more time on ventilators and in intensive care.

17 Nov 2011

Mediterranean diet can reduce risk of future heart disease

A team of Johns Hopkins researchers has uncovered further evidence of the benefits of a balanced diet that replaces white bread and pasta carbohydrates with unsaturated fat from avocados, olive oil and nuts — foods typical of the so-called "Mediterranean diet."

17 Nov 2011

Supervised exercise more effective than stenting or medication for PAD

Supervised exercise was shown to be more effective than stenting or medication for improved walking ability in patients with peripheral artery disease. The findings from a national study were reported today at the 2011 American Heart Association Scientific Sessions meeting.

17 Nov 2011

CIHR honors University of Calgary scientist with prestigious award for medical research

University of Calgary researcher Paul Kubes, PhD, is the recipient of one of Canada's top awards for medical research. An internationally-recognized scientist specializing in visualizing the mammalian immune system, Kubes will accept the 2011 Canada's Health Researcher of the Year award from the Canadian Institutes of Health Research (CIHR) at a ceremony in Ottawa this evening.

17 Nov 2011

Avraham raises $3M to advance ladostigil Phase II Alzheimer's trial

The drug, ladostigil, is a molecule that combines components from the existing drugs Azilect and Exelon. Teva's Azilect, for the treatment of Parkinson's disease, was developed by Prof. Emeritus Moussa Youdim of the Technion-Israel Institute of Technology. Azilect is the only anti-Parkinson's drug that has proven to have a disease-modifying effect. Novartis's Exelon was developed by Prof. Marta Weinstock-Rosin of Hebrew University to treat Alzheimer's disease.

17 Nov 2011

Cancer cells tap into natural recycling system to obtain energy

Researchers at Albert Einstein College of Medicine of Yeshiva University have discovered that cancer cells tap into a natural recycling system to obtain the energy they need to keep dividing. In a study with potential implications for cancer treatments, Einstein researchers used genetic manipulation to turn off this recycling system within the walls of cells and stop both tumor growth and metastasis.

17 Nov 2011

Drug-coated balloon restores blood flow in narrowed bare metal stent

A drug-coated balloon inserted in a narrowed bare metal stent is a promising therapy for restoring blood flow, according to research presented at the American Heart Association's Scientific Sessions 2011.

17 Nov 2011

Researchers uncover central component of fat metabolism

Obesity-related diseases are an increasing health problem. Researchers at the University of Oslo have now uncovered a central component of fat metabolism.

17 Nov 2011

Mycophenolate mofetil superior to azathioprine for lupus nephritis

A new large, international study finds that the immunosuppressant drug mycophenolate mofetil is superior to azathioprine, an older immunosuppressant, as a maintenance therapy for lupus nephritis.

17 Nov 2011

Multivitamin use linked to less healthy behaviors

The lack of evidence on multivitamin health benefits is no impediment to their widespread popularity, with over half the U.S. population popping such pills. This translates into a $27 billion industry, which lures consumers with the illusory promise of better health. But shocking new research suggests taking multivitamins might have the opposite effect -- not simply on the metabolic level, but on a metaphysical one: promoting a false sense of invulnerability that actually leads users to engage in riskier behaviors.

17 Nov 2011

CF Foundation, Genzyme announce new drug research agreement

Genzyme, a Sanofi company, and Cystic Fibrosis Foundation Therapeutics Inc., the nonprofit affiliate of the Cystic Fibrosis Foundation, today announced a research agreement to support the discovery of new drugs to treat people with the most common mutation found in patients with CF, Delta F508.

17 Nov 2011

Diallyl trisulfide may protect heart after attack

A component of garlic oil may help release protective compounds to the heart after heart attack, during cardiac surgery, or as a treatment for heart failure.

17 Nov 2011

New 2-DG-ABT combination cancer therapy triggers apoptosis

Researchers at the University of California, San Diego School of Medicine and Kyushu University Medical School say a novel combination of a specific sugar molecule with a pair of cell-killing drugs prompts a wide variety of cancer cell types to kill themselves, a process called apoptosis or programmed cell death.

17 Nov 2011